Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata) on August 4, 2016. The report serves to announce the Company's financial results for the second quarter of 2016 via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the attached press release (Exhibit 99.1), which is not included in the provided source text.
Material Changes
The filing does not contain specific data regarding material changes versus the prior comparable period. The document solely references the issuance of the Q2 2016 results announcement.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The report explicitly states that the information in Item 2.02 and Exhibit 99.1 is "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Verify the specific Q2 2016 financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 Press Release.
- Confirm the discrepancy between the metadata company name ("ACHIEVE LIFE SCIENCES, INC.") and the registrant name in the filing ("ONCOGENEX PHARMACEUTICALS, INC.").
- Review the full press release for any operational updates or clinical trial milestones not detailed in this summary.